Vera Therapeutics FY23 net loss $96.0M; raises $287.5M; Phase 3 on track

Vera Therapeutics, Inc.

FY 2023 net loss $96.0M ($2.25 diluted EPS) vs $89.1M ($3.35) prior year; no revenue.
Cash $160.7M at Dec 31, 2023; subsequent $287.5M gross from Feb 2024 offering.
Phase 2b 72-week data: sustained reductions in Gd-IgA1, hematuria, UPCR with stable eGFR; Phase 3 topline 1H 2025.
Appointed Robert M. Brenner, M.D. as CMO and William D. Turner as CDO.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vera Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income a net loss of $96.0 million, or a net loss per diluted share of $2.25, EPS net loss per diluted share of $2.25.

Period: the fourth quarter and full year ended December 31, 2023
Net income: a net loss of $96.0 million, or a net loss per diluted share of $2.25
EPS: net loss per diluted share of $2.25
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, the company reported a net loss of $96.0 million, or a net loss per diluted share of $2.25

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-033947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.